Matching articles for "Uloric"
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • October 30, 2023; (Issue 1688)
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi,...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • October 30, 2023; (Issue 1688)
...
View the Comparison Table: Some Drugs for Gout
Expanded Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • March 11, 2019; (Issue 1567)
...
View the Expanded Table: Some Drugs for Gout
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • November 6, 2017; (Issue 1533)
The FDA has approved Duzallo (Ironwood), a fixed-dose
combination of the uric acid transporter 1
(URAT1) inhibitor lesinurad (Zurampic) and the
xanthine oxidase inhibitor allopurinol (Zyloprim,...
The FDA has approved Duzallo (Ironwood), a fixed-dose
combination of the uric acid transporter 1
(URAT1) inhibitor lesinurad (Zurampic) and the
xanthine oxidase inhibitor allopurinol (Zyloprim, and
generics), for once-daily treatment of gout-associated
hyperuricemia in patients who have not achieved
target serum uric acid levels with allopurinol alone.
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • November 21, 2016; (Issue 1508)
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail...
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail to reach goal with xanthine oxidase
inhibitor monotherapy.
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • March 17, 2014; (Issue 1438)
The goals of gout treatment are threefold: treating
acute inflammation, preventing flares, and lowering serum
urate...
The goals of gout treatment are threefold: treating
acute inflammation, preventing flares, and lowering serum
urate levels.
Pegloticase (Krystexxa) for Treatment of Refractory Gout
The Medical Letter on Drugs and Therapeutics • February 7, 2011; (Issue 1357)
Pegloticase (Krystexxa – Savient), a PEGylated urate oxidase enzyme, has been approved by the FDA for intravenous (IV) treatment of chronic symptomatic gout in adults who have not responded to maximum doses...
Pegloticase (Krystexxa – Savient), a PEGylated urate oxidase enzyme, has been approved by the FDA for intravenous (IV) treatment of chronic symptomatic gout in adults who have not responded to maximum doses of a xanthine oxidase inhibitor, such as allopurinol (Zyloprim, and others). Pegloticase is the second new drug approved for gout in more than 40 years; a new xanthine oxidase inhibitor, febuxostat (Uloric), was approved in 2009.
Febuxostat (Uloric) for Chronic Treatment of Gout
The Medical Letter on Drugs and Therapeutics • May 18, 2009; (Issue 1312)
Febuxostat (Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40...
Febuxostat (Uloric - Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.